Tocagen Inc. (TOCA)
| Market Cap | 2.01M |
| Revenue (ttm) | 27,000 |
| Net Income (ttm) | n/a |
| Shares Out | 23.92M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jun 15, 2020 |
| Last Price | $1.26 |
| Previous Close | $1.26 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 1.22 - 1.50 |
| Day's Volume | 0 |
| 52-Week Range | 0.42 - 6.77 |
News
SAN DIEGO, May 28, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety...
Tocagen Inc. (TOCA) Tocagen and Forte Biosciences Announce Merger (Transcript)
Tocagen Inc (NASDAQ: TOCA) shares were tumbling to an all-time low Thursday following an adverse clinical trial readout.
Shares of Tocagen Inc. TOCA, +11.47% plummeted 82% on heavy volume toward a record low, enough to pace all premarket decliners Thursday, after the gene company said a late-stage trial of its b...
Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.
TOCAGEN INC (TOCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The final data read-out of Toca 5 Pivotal phase III trial in patient with Recurrent Brain Cancer anticipated in Q4 2019.
Investors overreacted to Tocagen’s recent announcement that an Independent Data Monitoring Committee (IDMC) gave its brain cancer drug clinical trials the go-ahead to continue.
Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.
An interim look at the company's experimental brain cancer treatment didn't reveal the result investors wanted.
Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.
Today, we take a "deep-dive" on an interesting developmental name in oncology named Tocagen based in sunny San Diego.
About TOCA
Tocagen, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase ... [Read more...]
| Industry Biotechnology | IPO Date Apr 13, 2017 |
| CEO Martin J. Duvall | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol TOCA |
Financial Performance
In 2019, Tocagen's revenue was $36,000, a decrease of -99.80% compared to the previous year's $18.04 million. Losses were -$63.52 million, 29.7% more than in 2018.